CENTOGENE to Participate in Upcoming Conferences in December
December 01, 2022 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
CENTOGENE Announces Changes to Supervisory Board, Including Appointment of Mary Sheahan
November 21, 2022 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
CENTOGENE to Participate in Upcoming Conferences in November
November 10, 2022 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network
November 03, 2022 06:00 ET
|
Centogene NV
Company’s launch of Biodata Network offers new portfolio of data-driven solutionsCollaboration with BC Platforms increases access to data-driven genomic insights via Global Data Partner Network,...
CENTOGENE to Participate in Upcoming Partnering Conferences in October
October 06, 2022 06:00 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and...
CENTOGENE Reaches 12,500 Patient Milestone in World’s Largest Observational Study on Parkinson’s Disease Genetics
October 03, 2022 08:00 ET
|
Centogene NV
Working together with Denali Therapeutics to accelerate data-driven precision medicine for the PD community Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics...
CENTOGENE to Present at Upcoming Investor & Partnering Conferences in September
September 01, 2022 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and...
CENTOGENE Reports First Quarter 2022 Financial Results
July 15, 2022 08:15 ET
|
Centogene NV
On Track for FY 2022 Guidance Q1 2022 revenue rises 3% to €10.3 million Completed phase out of COVID-19 Business segment in Q1 2022Positioning Pharma and Diagnostics for post-COVID recovery and...
CENTOGENE Announces Appointment of Miguel Coego Rios as Chief Financial Officer
June 27, 2022 16:01 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, June 27, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage, essential biodata life science partner for rare and...
CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting
June 27, 2022 16:01 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 27, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage, essential biodata life science partner for rare and...